Showing 2101-2110 of 4063 results for "".
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Awardhttps://modernod.com/news/valeda-light-delivery-system-receives-2019-medical-design-excellence-award/2476654/LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multicenter Clinical Trial for Treating Dry AMDhttps://modernod.com/news/lumithera-receives-notice-of-award-for-2-5-million-national-eye-institute-grant-to-support-u-s-multicenter-clinical-trial-for-treating-dry-amd/2476262/LumiThera announced that it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects
- For 2019, ADA and ACC Align Their Diabetes Recommendationshttps://modernod.com/news/for-2019-ada-and-acc-align-their-diabetes-recommendations/2476250/For the first time in its annual diabetes management guidelines, the American Diabetes Association (ADA) has aligned its recommendations with those of the American College of Cardiology (ACC) for cardiovascular risk reduction in people with type 2 diabetes, according to a report in Medscape.
- Oyster Point Announces Results of Phase 3 Trial of OC-01 Nasal Spray for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-results-of-phase-3-trial-of-oc-01-nasal-spray-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2477743/Oyster Point Pharma announced positive topline results from the phase 3 ONSET-2 study in dry eye disease. The ONSET-2 trial met the primary endpoint, where a greater percentage of subjects treate
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- BVI launches Finevision HP Trifocal IOL in Japanhttps://modernod.com/news/bvi-launches-finevision-hp-trifocal-iol-in-japan/2481681/BVI has announced the launch of the Finevision HP hydrophobic and glistening free trifocal IOL in Japan. BVI Japan will host the official launch event at the upcoming Japanese Society of Cataract and Refractive Surgeons (JSCRS) annual meeting in Sapporo, Japan, June 22-24. Dr. Kazu
- Luneau Technology Launches as 'Visionix' to Manufacture and Sell Optovue, Visionix, Briot and Weco Brandshttps://modernod.com/news/luneau-technology-launches-as-visionix-to-manufacture-and-sell-optovue-visionix-briot-and-weco-brands/2480736/Luneau Technology Group recently announced that it will take on 'Visionix' as its official global name beginning March 31, 2022, unveiling a combined booth at Vision Expo East. As mentioned in the recent global announcement, 'Optovue' will transition to a product brand f
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Optometry’s Meeting Cancelled Due to COVID-19https://modernod.com/news/optometrys-meeting-cancelled-due-to-covid-19/2477565/Out of an abundance of caution amid the ongoing COVID-19 pandemic, the American Optometric Association (AOA) has officially cancelled the annual Optometry’s Meeting, scheduled to take place on June 24-28 in Washington DC. The annual meeting of both the AOA and American Optometric Student As